Shield Therapeutics Management
Management criteria checks 3/4
Shield Therapeutics' CEO is Anders Lundstrom, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth £285.29. The average tenure of the management team and the board of directors is 1.6 years and 4 years respectively.
Key information
Anders Lundstrom
Chief executive officer
US$53.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.001% |
| Management average tenure | 1.6yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15CEO
Anders Lundstrom (62 yo)
less than a year
Tenure
US$53,542
Compensation
Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | less than a year | US$53.54k | 0.0013% £ 285.3 | |
| Co-Founder & Non Executive Director | 16.8yrs | US$47.17k | 1.49% £ 332.1k | |
| Chief Financial Officer | less than a year | no data | no data | |
| General Counsel & Company Secretary | 7.2yrs | no data | no data | |
| Group HR Director | no data | no data | no data | |
| Head of Pharmacovigilance & Medical Information | no data | no data | no data | |
| Chief Commercial Officer | 1.6yrs | no data | no data | |
| Senior Director of People & Culture | no data | no data | no data |
1.6yrs
Average Tenure
56.5yo
Average Age
Experienced Management: STX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Independent Non-Executive Director | 3.5yrs | US$53.54k | 0.0013% £ 285.3 | |
| Co-Founder & Non Executive Director | 4.4yrs | US$47.17k | 1.49% £ 332.1k | |
| Independent Non Executive Chairman | 6.3yrs | US$119.83k | 0.70% £ 156.7k | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 8.8yrs | US$76.49k | 0.023% £ 5.1k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.5yrs | US$47.17k | 0.035% £ 7.7k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data |
4.0yrs
Average Tenure
60yo
Average Age
Experienced Board: STX's board of directors are considered experienced (4 years average tenure).